Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Metrics to compare | NP5 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNP5PeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.3x | 1.8x | −0.7x | |
PEG Ratio | 0.06 | 0.01 | 0.00 | |
Price/Book | 196.4x | −0.4x | 2.6x | |
Price / LTM Sales | 5.2x | 4.1x | 3.4x | |
Upside (Analyst Target) | - | 15.7% | 39.1% | |
Fair Value Upside | Unlock | 11.6% | 5.5% | Unlock |